-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Monthly Archives: May 2011
BIO’s “What Every State Should Know About Bayh-Dole” Webinar
The Biotechnology Industry Organization (BIO) recently hosted a webinar entitled: “What Every State Should Know About Bayh-Dole: Leveraging University Research to Create Jobs and Spur Economic Development Benefits.” The Bayh-Dole Act, enacted in 1980, placed patent ownership of federally funded research at universities in the hands of the university and enabled universities to out-license technologies for commercialization. As a result of the Act, more than 7200 companies were created (including nearly 600 last year despite Read More >
Beware the Liability Gaps in Biotechnology M&As
Mike Yeager, Senior Underwriting Specialist, Chubb Mergers and acquisitions continue to be a source of growth for the biotechnology industry. Even the financial crisis has not significantly slowed this trend. In fact, a weakened global economy may have further fueled consolidation as biotechnology companies sought additional efficiencies in R&D, procurement or administration. Since many biotechnology companies have complex corporate structures—some with hundreds of subsidiaries—executives at acquiring companies recognize that along with the benefits of the Read More >
Bill Gates: Innovation is Key to Helping Poor Farmers
“I’ve never been a farmer,” Bill Gates confessed at The Chicago Council’s Symposium on Global Agriculture and Food Security. “Until recently, I rarely set foot on a farm.” Yet, through the Gates Foundation, he is one of the world’s most powerful advocates for poor farmers and he is helping them gain access to technology that will help them grow their way to self-sufficiency. Right now, the average farmer in sub-Saharan Africa produces just over a Read More >
Bonus: Monday Partnering!
Ifyou read our post about the partnering milestones for the BIO Business Forum this year, what we’re about to announce may not come as much surprise. The BIO Business Forum is adding a new member to the family: Monday. Originally, the event was taking place from Tuesday, the 28th until Thursday, the 30th. But due to the trend we’re seeing, it’s clear to us that you simply want more meetings. Opening Monday as an additional Read More >
Huffington Post: Data Exclusivity: Getting the Balance Right
Huffington Post: Data Exclusivity: Getting the Balance Right A great article on the downsides of cutting or removing data exclusivity provisions for biologics. The article points out that data protection is needed to enhance safety and create incentives to research and produce new innovative drugs that cost billions of dollars. However, the author argues that the period must be limited somehow (not 50 years) to ensure generics can entire the market and lower costs. Finally, the author states that lowering the data exclusivity Read More >
